TransCode Therapeutics, Inc. Share Price & Technical Analysis
RNAZ · $6.24 (+1.96%)
Healthcare / Biotechnology
$6.24
+1.96%
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its …
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
-26% return in May, 37% avg return in past 3 year May month.
-1% return in 2026, -144% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 42% | 1% | -8% | -10% | -26% | – | – | – | – | – | – | – | -1% |
| 25 | 125% | -72% | -75% | -14% | -49% | 15% | 39% | -10% | 14% | 2% | -16% | -27% | -70% |
| 24 | -89% | -2% | -2% | -8% | 193% | -41% | -72% | -8% | 118% | -18% | -25% | -69% | -24% |
| 23 | 15% | -49% | -32% | -4% | -34% | -44% | -4% | -32% | -66% | -28% | -30% | -29% | -338% |
| 22 | -9% | -8% | 33% | -9% | -34% | -32% | 13% | -11% | -8% | -42% | -42% | 57% | -91% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Oversold
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$6.41M
P/E ratio
—
52W high
$20.99
52W low
$5.56
Volume
7,730
Beta
1.40
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is TransCode Therapeutics, Inc. share price today?
- TransCode Therapeutics, Inc. (RNAZ) last traded around $6.24 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does RNAZ have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for RNAZ. Download the app for real-time alerts.
- How can I analyze TransCode Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.